379 related articles for article (PubMed ID: 8713795)
1. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
2. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN
Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181
[TBL] [Abstract][Full Text] [Related]
3. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
4. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
6. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
7. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.
Gandossi E; Lunven C; Berry CN
Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104
[TBL] [Abstract][Full Text] [Related]
8. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
Cella G; Girolami A; Sasahara AA
Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
[No Abstract] [Full Text] [Related]
9. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
10. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
Imiya M; Matsuo T
Thromb Res; 1997 Oct; 88(2):245-50. PubMed ID: 9361377
[TBL] [Abstract][Full Text] [Related]
13. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
[TBL] [Abstract][Full Text] [Related]
14. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
15. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
He S; Blombäck M; Bark N; Johnsson H; Wallén NH
Thromb Haemost; 2010 May; 103(5):1076-84. PubMed ID: 20216982
[TBL] [Abstract][Full Text] [Related]
16. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
17. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
[TBL] [Abstract][Full Text] [Related]
18. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
20. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
